Abstract
In recent years, genes associated with cancer have been studied to assess their possible use as predictive indicators for cancer therapies. Among these, the gene product of the tumor suppressor gene p53 was found to play an important role in cancer therapy. The p53 molecule induces cell-cycle arrest, apoptosis and DNA repair after cells are subjected to cancer therapies involving radiation, heat and various anti-cancer agents. Mutations in p53 are observed at a high frequency in human tumors, and are present in about half of all malignant tumors in humans. Sensitization to radiation, heat and anti-cancer agents was observed in cells containing wild type p53, but not in cells containing mutated p53. This review discusses p53 activation of signaling pathways after exposure to cancer therapies which target p53; such therapies include chemical chaperones, the p53 gene, p53-C terminal peptides, and p53-targeting agents which enhance p53-central signal transduction pathways.
Keywords: p53, chemical chaperones, apoptosis, radiation, heat
Anti-Cancer Agents in Medicinal Chemistry
Title: p53 Targeting Can Enhance Cancer Therapy via Radiation, Heat and Anti-Cancer Agents
Volume: 8 Issue: 5
Author(s): Takeo Ohnishi, Akihisa Takahashi, Eiichiro Mori and Ken Ohnishi
Affiliation:
Keywords: p53, chemical chaperones, apoptosis, radiation, heat
Abstract: In recent years, genes associated with cancer have been studied to assess their possible use as predictive indicators for cancer therapies. Among these, the gene product of the tumor suppressor gene p53 was found to play an important role in cancer therapy. The p53 molecule induces cell-cycle arrest, apoptosis and DNA repair after cells are subjected to cancer therapies involving radiation, heat and various anti-cancer agents. Mutations in p53 are observed at a high frequency in human tumors, and are present in about half of all malignant tumors in humans. Sensitization to radiation, heat and anti-cancer agents was observed in cells containing wild type p53, but not in cells containing mutated p53. This review discusses p53 activation of signaling pathways after exposure to cancer therapies which target p53; such therapies include chemical chaperones, the p53 gene, p53-C terminal peptides, and p53-targeting agents which enhance p53-central signal transduction pathways.
Export Options
About this article
Cite this article as:
Ohnishi Takeo, Takahashi Akihisa, Mori Eiichiro and Ohnishi Ken, p53 Targeting Can Enhance Cancer Therapy via Radiation, Heat and Anti-Cancer Agents, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (5) . https://dx.doi.org/10.2174/187152008784533017
DOI https://dx.doi.org/10.2174/187152008784533017 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Modifications of Icosahedral Plant Virus-based Nanoparticles for Vaccine and Immunotherapy Applications
Current Protein & Peptide Science Realizing the Potential of Blueberry as Natural Inhibitor of Metastasis and Powerful Apoptosis Inducer: Tapping the Treasure Trove for Effective Regulation of Cell Signaling Pathways
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Development of P-gp Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Mucoadhesive Nanoparticulate System for Oral Drug Delivery: A Review
Current Drug Therapy Structural Magnetic Resonance Imaging Findings in Posttraumatic Stress Disorder and Their Response to Treatment: A Systematic Review
Current Psychiatry Reviews Meta-Analysis of Anticancer Drug Structures - Significance of Their Polar Allylic Moieties
Anti-Cancer Agents in Medicinal Chemistry Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Current Medicinal Chemistry “Non-Taxifolin” Derived Flavonolignans: Phytochemistry and Biology
Current Pharmaceutical Design Adenosine in the Central Nervous System: Effects on Neurotransmission and Neuroprotection
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Exploiting Innate γδ T Lymphocytes for Tumor Immunotherapy
Recent Patents on Biomarkers The Injured Cochlea as a Target for Inflammatory Processes, Initiation of Cell Death Pathways and Application of Related Otoprotective Strategies
Recent Patents on CNS Drug Discovery (Discontinued) Smart Inulin-Based Polycationic Nanodevices for siRNA Delivery
Current Drug Delivery Herbal Medicine of the 21st Century: A Focus on the Chemistry, Pharmacokinetics and Toxicity of Five Widely Advocated Phytotherapies
Current Topics in Medicinal Chemistry The Role of Cytochrome P450 in Cytotoxic Bioactivation: Future Therapeutic Directions
Current Cancer Drug Targets Intra - and Intercellular Calcium Handling in Pulmonary Arterial Hypertension
Medicinal Chemistry Tumor-selective Cytotoxicity of a Novel Pentadiene Analogue on Human Leukemia/lymphoma Cells
Clinical Cancer Drugs Proteolytic Enzymes and Their Inhibition in Epithelial Ovarian Cancer
Current Enzyme Inhibition PIM1 Kinase as a Target in Prostate Cancer: Roles in Tumorigenesis, Castration Resistance, and Docetaxel Resistance
Current Cancer Drug Targets Cu-mediated synthesis of 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-1-ones as potential inhibitors of sirtuins
Letters in Drug Design & Discovery Emerging Technologies for Cancer Research: Towards Personalized Medicine with Microfluidic Platforms and 3D Tumor Models
Current Medicinal Chemistry